Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Net Asset Quality Index
Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Net Asset Quality Index of 60.2% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.91 Billion minus total liabilities of CN¥757.69 Million yields net assets of CN¥1.15 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can Shaanxi Meibang Pharmaceutical Group Co fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shaanxi Meibang Pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2017–2024)
This chart shows how Shaanxi Meibang Pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 8 annual periods from 2017 to 2024. As of September 2025, the index stands at 60.2%, representing net assets of CN¥1.15 Billion against total assets of CN¥1.91 Billion CNY. Explore 605033 operating cash flow to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
The table below presents the year-by-year Net Asset Quality Index for Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024, covering 8 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shaanxi Meibang Pharmaceutical Group Co (605033) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 60.4% | CN¥1.12 Billion | CN¥1.86 Billion | CN¥737.37 Million | ▼ -5.4 pp |
| 2023 | 65.8% | CN¥1.11 Billion | CN¥1.69 Billion | CN¥577.84 Million | ▼ -3.8 pp |
| 2022 | 69.6% | CN¥1.09 Billion | CN¥1.56 Billion | CN¥474.14 Million | ▲ +3.5 pp |
| 2021 | 66.1% | CN¥966.95 Million | CN¥1.46 Billion | CN¥496.43 Million | ▲ +8.9 pp |
| 2020 | 57.2% | CN¥449.37 Million | CN¥785.87 Million | CN¥336.50 Million | ▲ +1.5 pp |
| 2019 | 55.7% | CN¥370.63 Million | CN¥665.97 Million | CN¥295.34 Million | ▲ +8.5 pp |
| 2018 | 47.2% | CN¥276.37 Million | CN¥585.78 Million | CN¥309.40 Million | ▲ +11.8 pp |
| 2017 | 35.4% | CN¥180.43 Million | CN¥509.66 Million | CN¥329.23 Million | — |